Back
Leon Wang
Executive Vice President of International & China President, AstraZeneca

AstraZeneca EVP: Global cooperation is the only feasible solution to a global health crisis

🎥 Apr 22, 2022 📺 CGTN ⏱ 1m
For more: https://news.cgtn.com/news/2022-04-22... Global efforts to fight COVID-19 in recent years have been described as unprecedented. Leon Wang is the Executive Vice President for the International Region at AstraZeneca. He said global communities can definitely help each other, and governmental and institutional support is crucial. Subscribe to us on YouTube: https://goo.gl/lP12gA Download our APP on Apple Store (iOS): https://itunes.apple.com/us/app/cctvn... Download our APP on Google Play (Android): https://play.google.com/store/apps/de...
Watch on YouTube

About Leon Wang

In April 2022, Leon Wang, Executive Vice President for the International Region at AstraZeneca, stated that global cooperation is the only feasible solution to a global health crisis. He said that the global community can help each other through technology transfer of vaccines, antiviral drug manufacturing, and treatment antibody supply. Wang argued that technology should not create a barrier and that equal access to medication, vaccines, and treatment should be provided to both developed countries and emerging markets. Wang also called for collaboration on supply capacity, stating that countries should not have border barriers or regulatory approval barriers and that capacity should be shared among countries. He noted the importance of government and healthcare professional support for minority patients, including oncology, hematology, and renal dialysis patients, and said that such support would generate a long-term impact.

Source: AI-verified profile updated from Leon Wang's recent appearances. Browse all interviews →

Transcript (2 segments)
L
Leon Wang0:11
In manufacturing and also the treatment antibody supply, I think technology we should not create a barrier for technology and making sure that equal access of medication, vaccine, and treatment are really provided to not only developed countries but also emerging markets. At the same time, I think we need to collaborate also on the capacity of supplying these important prevention and treatment, so country with country should not have a border barrier and also regulatory approval barrier. So we really need to help each other to make sure that the capacity can be shared.
Support will in the future ultimately generate a long-term impact to the importance of helping these people.